Home › Research › Tau biomarkers
Increased CAIDE dementia risk, cognition, CSF biomarkers, and vascular burden in healthy adults
Ecay-Torres M, Estanga A, Tainta M, Izagirre A, Garcia-Sebastian M, Villanua J, Clerigue M, Iriondo A et al.. Neurology, 2018-06-13
Topic: Risk, prevention and care in population studies
Objective To investigate the cognitive profile of healthy individuals with increased Cardiovascular Risk Factors, Aging and Dementia (CAIDE) dementia risk score and to explore whether this association is related to vascular burden and CSF biomarkers of amyloidosis and neurodegeneration. Method Cognitively normal participants (mean age 57.6 years) from the Gipuzkoa Alzheimer Project study were classified as having high risk (HR; n = 82) or low risk (LR; n = 293) for dementia according to a CAIDE score cutoff of 9. Cognitive composites were compared between groups.
Key findings
- Method Cognitively normal participants (mean age 57.6 years) from the Gipuzkoa Alzheimer Project study were classified as having high risk (HR; n = 82) or low risk (LR; n = 293) for dementia according to a CAIDE score cutoff of 9.
- Cognitive composites were compared between groups.
- We explored using generalized linear models the role of APOE genotype, MRI white matter hyperintensities (WMH), and CSF (n = 218) levels of β-amyloid 1-42 (Aβ 1-42 ), total tau (t-tau), and phosphorylated tau (p-tau) in the association between CAIDE score and cognition.
- Results HR participants obtained lower scores on executive function (EF) ( p = 0.001) and visual perception and construction (VPC) ( p p = 0.001), CAIDE score × t-tau ( p = 0.001), and WMH ( p = 0.003).
Why it matters
Healthy adults with a higher CAIDE dementia risk score were compared with lower-risk adults on cognition, vascular burden and cerebrospinal fluid markers of amyloid and neurodegeneration. The study examined associations only, so it cannot show whether reducing this risk score or these markers would prevent dementia.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants82
- Evidence strengthLow
How this study scored 48/100
Published in a leading specialty journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 1 / 4 | 82 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 37 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.7 citations a year over 10 year(s) since 2018 |
| Impact for its field and year | 2 / 6 | Cited 2.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 5 other studies in this library |
| Still being cited | 2 / 4 | Cited 16 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Pablo Martínez‐Lage: h-index 45 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Karolinska Institutet: institution h-index 1,477 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 29898969) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Ecay-Torres, M., Estanga, A., Tainta, M., Izagirre, A., Garcia-Sebastian, M., Villanua, J., et al. (2018). Increased CAIDE dementia risk, cognition, CSF biomarkers, and vascular burden in healthy adults. Neurology. https://doi.org/10.1212/wnl.0000000000005824
Vancouver
Ecay-Torres M, Estanga A, Tainta M, Izagirre A, Garcia-Sebastian M, Villanua J, et al. Increased CAIDE dementia risk, cognition, CSF biomarkers, and vascular burden in healthy adults. Neurology. 2018. doi:10.1212/wnl.0000000000005824. PMID: 29898969.
BibTeX
@article{ecaytorres2018-29898969,
author = {Ecay-Torres, M. and Estanga, A. and Tainta, M. and Izagirre, A. and Garcia-Sebastian, M. and Villanua, J. and Clerigue, M. and Iriondo, A. and others},
title = {{Increased CAIDE dementia risk, cognition, CSF biomarkers, and vascular burden in healthy adults}},
journal = {Neurology},
year = {2018},
doi = {10.1212/wnl.0000000000005824},
pmid = {29898969},
url = {https://doi.org/10.1212/wnl.0000000000005824}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
5 studies in the alzhub library list this one in their references.
Related studies in Tau biomarkers
Also tagged “biomarkers”
821 studies in the library carry the topic tag “biomarkers”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.